AbCellera Biologics Inc. (ABCL) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA00288U1066
AbCellera Biologics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 75.13 m USD |
| Operating income | -217.10 m USD |
| EBIT | -205.92 m USD |
| Net income | -146.41 m USD |
| Diluted EPS – continuing operations | -0.49 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
More stocks
- Yamaha Corp (7951.T)
- ZIM Integrated Shipping Services Ltd (ZIM)
- Shanxi Coal International Energy Group Co Ltd (600546.SS)
- STO Express Co Ltd (002468.SZ)
- ASHLAND INC. (ASH)
- Air France KLM SA (AF.PA)
- Carl Zeiss Meditec (AFX.DE)
- COMMUNITY FINANCIAL SYSTEM, INC. (CBU)
- Shandong Weigao Blood (603014.SS)
- China World Trade Center Co Ltd (600007.SS)
- Tikehau Capital SCA (TKO.PA)
- GPGI, Inc. (GPGI)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.